Drug Profile
Influenza A virus vaccine H5N1 - Chengdu Kanghua Biological Products
Alternative Names: H5N1 Influenza Vaccine - Chengdu Kanhua Biological Products; Split virion influenza vaccine - Chengdu Kanghua Biological ProductsLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Chengdu Kanghua Biological Products
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for clinical-Phase-Unknown development in Influenza-A-virus-H5N1-subtype in China (Parenteral, Injection)
- 24 Sep 2015 Chengdu Kanhua Biological Products completes clinical develoment of H5N1 influenza vaccine before September 2015 (Chengdu Kanhua Biological Products website, September 2015)
- 04 Sep 2015 Clinical trials in Influenza-A virus H5N1 subtype in China (Parenteral) before September 2015